Skip to content

COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty

Total Knee Anthroplasty | Bilateral Knee Osteoarthritis | Osteoarthritis (OA) of the Knee | Osteoarthritis(primary)

Through a triple-blinded randomized control trial, the primary purpose of this pilot study is to assess the efficacy of administering peri-operative contralateral corticosteroid injection in patients undergoing TKA. The secondary outcome was to assess the effect of contralateral corticosteroid injection on pain and functional outcomes of patients undergoing TKA.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Patients 18 years of age and older
* Primary osteoarthritis diagnosis with indication for primary elective unilateral TKA
* No previous contralateral knee injections (steroids/biologics) within one year of study
* Not scheduled for bilateral TKA or a subsequent staged contralateral TKA within the next six months
* No previous or active infection or trauma (osseous/ligamentous/extensor mechanism) on the contralateral knee
* Contralateral knee pain \& symptoms - defined as a VAS of \>4/10 at initial pre-op visit
* Contralateral knee OA quantified as: Kellgren and Lawrence grade \>2-4

* Assessed by PI (AK) who will not be contributing any patients to the study through examination of blinded knee radiographs (3 views: AP/lateral/Sunrise)
* Patient is able to read and understand English and provide informed consent to participation in the study

Exclusion Criteria:

* Other aetiologies of OA that warrants TKA (inflammatory or post traumatic arthritis)
* Cognitive impairment (dementia, Alzheimer's, uncontrolled delirium) which will prevent patients from completing primary outcome measure or comply with follow-up requirements
* Previous TKA or ORIF or nailing on either knee
* Previous or active knee infection or extensor mechanism disruption
* Previous arthroscopy on either knee
* Medical contraindication to elective TKA surgery

Study Location

St. Michael's Hospital
St. Michael's Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Amir Khoshbin, MD, FRCS (C)

[email protected]
416-864-5265
Backup Contact

Cassandra Tardif-Theriault, BKin

[email protected]
416-864-6060
Backup Contact

Amir Khoshbin, MD, FRCS (C)

Study Sponsored By
Unity Health Toronto
Participants Required
More Information
Study ID: NCT06809998